Inflammatory Breast Cancer

  • Jessica C. Gooch
  • Freya SchnabelEmail author


Inflammatory breast cancer is a rare presentation of invasive breast cancer and has a poor prognosis. After a thorough workup, including imaging and a biopsy which demonstrates involved dermal lymphatics, the patient should begin neoadjuvant chemotherapy. Total mastectomy and axillary node dissection are the most likely course of surgical management. Patients who are either ER/PR or HER-2/neu positive may benefit from the addition of targeted therapy, although most inflammatory cancers are triple negative. Patients are at significant risk of recurrence and/or metastatic disease and should be followed closely.


Inflammatory Cancer Breast Dermal lymphatics Neoadjuvant Modified radical mastectomy 


  1. 1.
    Dawood S, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol. 2011;22(3):515–23.CrossRefGoogle Scholar
  2. 2.
    van Uden DJ, et al. Inflammatory breast cancer: an overview. Crit Rev Oncol Hematol. 2015;93(2):116–26.CrossRefGoogle Scholar
  3. 3.
    Yamauchi H, et al. Inflammatory breast cancer: what we know and what we need to learn. Oncologist. 2012;17(7):891–9.CrossRefGoogle Scholar
  4. 4.
    Network NCC. NCCN – evidence blocks – inflammatory breast cancer, in NCCN guidelines version 2.2016 – Invasive breast cancer. 2016. p. 1–2.Google Scholar
  5. 5.
    Cancer AJCO. Breast cancer staging. 8th ed: Chicago, Illinois: A. C. Society; 2017.Google Scholar
  6. 6.
    Wecsler JS, et al. Lymph node status in inflammatory breast cancer. Breast Cancer Res Treat. 2015;151(1):113–20.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of SurgeryNYU Langone Health, NYU Perlmutter Cancer CenterNew YorkUSA

Personalised recommendations